REFERENCES
1. Ferneini EM. Medication-related osteonecrosis of the jaw (MRONJ). J Oral Maxillofac Surg. 2021;79:1801-2.
2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022;80:920-43.
3. Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021;153:116184.
4. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432.
5. Ali IE, Sumita Y. Medication-related osteonecrosis of the jaw: prosthodontic considerations. Jpn Dent Sci Rev. 2022;58:9-12.
6. Bansal H. Medication-related osteonecrosis of the jaw: an update. Natl J Maxillofac Surg. 2022;13:5-10.
7. Boston B, Ipe D, Capitanescu B, et al. Medication-related osteonecrosis of the jaw: a disease of significant importance for older patients. J Am Geriatr Soc. 2023;71:2640-52.
8. Bedogni A, Mauceri R, Fusco V, et al. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. 2024;30:3679-709.
9. Mohd Yunus SS, Soh HY, Abdul Rahman M, Peng X, Guo C, Ramli R. MicroRNA in medication related osteonecrosis of the jaw: a review. Front Physiol. 2023;14:1021429.
10. Rosenberg SA, Migliorati C, Romanos GE. Is medication-related osteonecrosis of the jaw associated with tumor necrosis factor-α inhibition? Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;131:422-7.
11. Roato I, Mauceri R, Notaro V, Genova T, Fusco V, Mussano F. Immune dysfunction in medication-related osteonecrosis of the jaw. Int J Mol Sci. 2023;24:7948.
12. Kün-Darbois JD, Fauvel F. Medication-related osteonecrosis and osteoradionecrosis of the jaws: update and current management. Morphologie. 2021;105:170-87.
13. Byrne H, O'Reilly S, Weadick CS, Brady P, Ríordáin RN. How we manage medication-related osteonecrosis of the jaw. Eur J Med Res. 2024;29:402.
14. Migliorati CA. Oral complications in cancer patients-medication-related osteonecrosis of the jaw (MRONJ). Front Oral Health. 2022;3:866871.
15. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
16. Igelström E, Campbell M, Craig P, Katikireddi SV. Cochrane's risk of bias tool for non-randomized studies (ROBINS-I) is frequently misapplied: a methodological systematic review. J Clin Epidemiol. 2021;140:22-32.
17. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
18. Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg. 2012;70:1573-83.
19. Giudice A, Barone S, Giudice C, Bennardo F, Fortunato L. Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126:390-403.
20. Mozzati M, Arata V, Gallesio G. Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int. 2013;24:1707-12.
21. Mücke T, Deppe H, Hein J, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. J Craniomaxillofac Surg. 2016;44:1689-93.
22. Ohbayashi Y, Iwasaki A, Nakai F, Mashiba T, Miyake M. A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration. Osteoporos Int. 2020;31:577-85.
23. Park JH, Kim JW, Kim SJ. Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2017;75:1176-84.
24. Poxleitner P, Steybe D, Kroneberg P, et al. Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2020;48:444-51.
25. Ristow O, Rückschloß T, Moratin J, et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot trial. Oral Dis. 2021;27:532-46.
26. Sahin O, Akan E, Tatar B, et al. Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol. 2022;88:613-20.
27. Sim IW, Borromeo GL, Tsao C, et al. Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol. 2020;38:2971-80.
28. Soutome S, Yanamoto S, Sumi M, et al. Effect of periosteal reaction in medication-related osteonecrosis of the jaw on treatment outcome after surgery. J Bone Miner Metab. 2021;39:302-10.
29. Varoni EM, Lombardi N, Villa G, Pispero A, Sardella A, Lodi G. Conservative management of medication-related osteonecrosis of the jaws (MRONJ): a retrospective cohort study. Antibiotics. 2021;10:195.
30. Yüce MO, Adalı E, ISık G. The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clin Oral Investig. 2021;25:4529-41.
31. Nisi M, La Ferla F, Karapetsa D, et al. Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: a series of 120 patients. Br J Oral Maxillofac Surg. 2016;54:930-5.
32. Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C. Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg. 2017;55:787-92.
33. Reich W, Bilkenroth U, Schubert J, Wickenhauser C, Eckert AW. Surgical treatment of bisphosphonate-associated osteonecrosis: prognostic score and long-term results. J Craniomaxillofac Surg. 2015;43:1809-22.
34. Hayashida S, Yanamoto S, Fujita S, et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab. 2020;38:126-34.
35. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022;7:CD012432.
36. Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7:47.
37. Kuroshima S, Al-Omari FA, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: a literature review and update. Genesis. 2022;60:e23500.
